Inhibikase Therapeutics Files S-1 Registration
Ticker: IKT · Form: S-1 · Filed: Jun 18, 2024 · CIK: 1750149
Sentiment: neutral
Topics: s-1, registration, sec-filing, pharmaceuticals
TL;DR
Inhibikase Therapeutics just filed an S-1, looks like they're raising cash.
AI Summary
Inhibikase Therapeutics, Inc. filed an S-1 registration statement on June 18, 2024, to register an unspecified number of securities. The company, headquartered in Atlanta, GA, is focused on developing therapies, with its principal executive offices located at 3350 Riverwood Parkway SE, Suite 1900. Milton H. Werner, Ph.D. serves as President and CEO.
Why It Matters
This S-1 filing indicates Inhibikase Therapeutics is preparing to offer new securities, potentially for fundraising to advance its drug development pipeline.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which can dilute existing shareholders or signal a need for capital, carrying inherent investment risks.
Key Numbers
- 333-280317 — SEC File Number (Identifies the specific SEC registration for this filing.)
- 26-3407249 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- Milton H. Werner, Ph.D. (person) — President and Chief Executive Officer
- 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 (company) — Principal Executive Offices
- McDermott Will & Emery LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1 filing for Inhibikase Therapeutics?
The S-1 filing is a registration statement filed with the SEC to register securities for public offering, indicating the company's intent to raise capital.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on June 18, 2024.
Who is the President and CEO of Inhibikase Therapeutics?
Milton H. Werner, Ph.D. is the President and Chief Executive Officer of Inhibikase Therapeutics, Inc.
Where are Inhibikase Therapeutics' principal executive offices located?
The company's principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339.
What is the Standard Industrial Classification code for Inhibikase Therapeutics?
The company's Primary Standard Industrial Classification Code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 4,606 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-06-18 17:27:36
Key Financial Figures
- $0.001 — 1,904 shares of common stock, par value $0.001 per share (the Common Stock), of Inhibi
- $1.68 — cement Warrant has an exercise price of $1.68 per share of Common Stock and will beco
- $1.55 — rted sale price of our Common Stock was $1.55 per share. We are an emerging growth
- $0.39 million — the National Institutes of Health, for $0.39 million to fund animal model studies of Risvode
- $7.66 billion — he global PAH market size was valued at $7.66 billion in 2023 and is estimated to grow at a c
- $1.625 million — milestone payments and seeks damages of $1.625 million in milestone payments plus interest. We
- $900,000 — eking damages or offset of no less than $900,000. The parties have agreed to mediate bef
Filing Documents
- d804510ds1.htm (S-1) — 303KB
- d804510dex51.htm (EX-5.1) — 11KB
- d804510dex1019.htm (EX-10.19) — 16KB
- d804510dex1020.htm (EX-10.20) — 23KB
- d804510dex231.htm (EX-23.1) — 2KB
- d804510dexfilingfees.htm (EX-FILING FEES) — 16KB
- g804510g0619015852393.jpg (GRAPHIC) — 3KB
- g804510g0619020141274.jpg (GRAPHIC) — 3KB
- g804510g22l15.jpg (GRAPHIC) — 574KB
- 0001193125-24-163529.txt ( ) — 1167KB
Risk Factors
Risk Factors 8 Special Note Regarding Forward-Looking Statements 10 Market, Industry And Other Data 13
Use Of Proceeds
Use Of Proceeds 14 Market Price of Our Common Stock and Related Stockholder Matters 15 Private Placement of Private Common Warrants 16 Warrant Repricing 18 Selling Stockholder 20 Plan of Distribution 22
Description of Capital Stock
Description of Capital Stock 24 Legal Matters 31 Experts 31 Where you Can Find Additional Information 31 Material Changes 31 Incorporation of Certain Information by Reference 32 i Table of Contents ABOUT THIS PROSPECTUS The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any related free writing prospectus is delivered or securities are sold on a later date. We have not done anything that would permit this offering or